<?xml version="1.0" encoding="UTF-8"?>
<p>Ranpirnase is currently being repurposed as an antiviral drug and is under investigation for broad spectrum activity against double-stranded DNA viruses [
 <xref rid="B15-viruses-12-00177" ref-type="bibr">15</xref>], retroviruses [
 <xref rid="B16-viruses-12-00177" ref-type="bibr">16</xref>,
 <xref rid="B17-viruses-12-00177" ref-type="bibr">17</xref>], and single-stranded RNA viruses including Ebola virus [
 <xref rid="B18-viruses-12-00177" ref-type="bibr">18</xref>]. Phase I and II clinical trials have been completed for the topical use of ranpirnase for the treatment of external genital warts caused by human papillomavirus [
 <xref rid="B15-viruses-12-00177" ref-type="bibr">15</xref>]. In the case of Ebola virus, ranpirnase inhibited replication of the virus in cell culture and protected mice when administered pre- and postexposure [
 <xref rid="B18-viruses-12-00177" ref-type="bibr">18</xref>]. 
</p>
